Literature DB >> 7882463

Determination of platinum in plasma of patients affected by inoperable lung carcinoma treated with radiotherapy and concurrent low-dose continuous infusion of cis-dichlorodiammine platinum(II).

F Morazzoni1, C Canevali, I Moschetti, R Todeschini, S Caroli, A Alimonti, F Petrucci, G Ravasi, A V Bedini, F Milani.   

Abstract

Platinum microquantities were determined in plasma of patients affected by lung carcinoma during treatment with radiotherapy (RT) and concurrent low-dose continuous infusion of cis-dichlorodiammineplatinum(II) (CDDP). RT was given at 50 Gy in continuous course; CDDP was continuously infused at 4 mg/m2 daily for 100 h/week for 5 weeks, and the infusions were separated by 68 h of rest. The percentage of free drug versus total drug in plasma was about 3%. It did not vary with therapy duration and was not significantly different from that found in 5-day continuous infusions at much higher daily doses. Nevertheless, maximal values of free Pt in plasma were very low and agreed with the low level of CDDP toxicity encountered on the present administration schedule.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882463     DOI: 10.1007/BF00686840

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Maximum tolerated dose for low-dose continuous infusion cisplatin.

Authors:  M B Hazuka; P A Bunn; J Crowley
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-08       Impact factor: 7.038

2.  A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.

Authors:  C Dominici; F Petrucci; S Caroli; A Alimonti; A Clerico; M A Castello
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

3.  Measurement of free-circulating cis-dichlorodiammineplatinum(II) in plasma.

Authors:  S J Bannister; L A Sternson; A J Repta; G W James
Journal:  Clin Chem       Date:  1977-12       Impact factor: 8.327

4.  Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy.

Authors:  W J Curran; P M Stafford
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

5.  Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer.

Authors:  D H Johnson; L H Einhorn; A Bartolucci; R Birch; G Omura; C A Perez; F A Greco
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

6.  Chemotherapeutic agent cisplatin monitoring in biological fluids by means of inductively-coupled plasma emission spectrometry (ICP-AES).

Authors:  C Dominici; A Alimonti; S Caroli; F Petrucci; M A Castello
Journal:  Clin Chim Acta       Date:  1986-08-15       Impact factor: 3.786

7.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer.

Authors:  C Schaake-Koning; W van den Bogaert; O Dalesio; J Festen; J Hoogenhout; P van Houtte; A Kirkpatrick; M Koolen; B Maat; A Nijs
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

8.  Non-resectable Stage IIIa-b lung carcinoma: a phase II study on continuous infusion of cisplatin and concurrent radiotherapy (plus adjuvant surgery).

Authors:  A V Bedini; L Tavecchio; F Milani; A Gramaglia; C Spreafico; A Marchianò; G Ravasi
Journal:  Lung Cancer       Date:  1993-10       Impact factor: 5.705

9.  Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.

Authors:  J F Belliveau; M R Posner; L Ferrari; G W Crabtree; F J Cummings; M C Wiemann; G P O'Leary; H Griffin; M A Phaneuf; A O'Rourke
Journal:  Cancer Treat Rep       Date:  1986-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.